Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
July 09, 2024 20:00 ET
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
July 02, 2024 08:00 ET
|
Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a...
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
March 20, 2024 02:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative...
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
March 12, 2024 12:00 ET
|
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
February 07, 2024 08:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
January 18, 2024 08:00 ET
|
KIZOO Technology Capital GmbH
SAN FRANCISCO and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Reservoir Neuroscience announced today the completion of a $4M financing round to support the development of new therapies for age-related...
Neuronic Welcomes Light Therapy Experts to its Scientific Advisory Board
August 31, 2023 10:00 ET
|
Neuronic Devices Operations GmbH
EGG HARBOR, N.J, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Neuronic, a pioneering company in the field of photobiomodulation (PBM) technology, also known as light therapy, is proud to announce the...
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
August 23, 2023 17:21 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
May 11, 2023 12:00 ET
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...